肿瘤治疗用工程化 T 细胞。
Engineered T cells for cancer treatment.
机构信息
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and The Methodist Hospital, Houston, Texas, USA.
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and The Methodist Hospital, Houston, Texas, USA.
出版信息
Cytotherapy. 2014 Jun;16(6):713-33. doi: 10.1016/j.jcyt.2013.10.002. Epub 2013 Nov 13.
Abstract
Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.
摘要
过继转移的 T 细胞具有转移到远处肿瘤部位、浸润纤维组织和杀伤表达抗原的肿瘤细胞的能力。不同的研究团队已经研究了各种旨在提高肿瘤特异性、增强 T 细胞效力、改善增殖、持久性或迁移能力以及提高安全性的基因工程策略。本文重点介绍 T 细胞工程的最新进展，讨论这些工程化细胞产品的临床应用，并概述该治疗模式的未来前景。
相似文献
1
Engineered T cells for cancer treatment.肿瘤治疗用工程化 T 细胞。
Cytotherapy. 2014 Jun;16(6):713-33. doi: 10.1016/j.jcyt.2013.10.002. Epub 2013 Nov 13.
2
CAR T-cell Therapy: A New Era in Cancer Immunotherapy.嵌合抗原受体T细胞疗法：癌症免疫疗法的新时代。
Curr Pharm Biotechnol. 2018;19(1):5-18. doi: 10.2174/1389201019666180418095526.
3
A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy.一种用于异基因联合免疫治疗的多药耐药工程化嵌合抗原受体T细胞
Mol Ther. 2015 Sep;23(9):1507-18. doi: 10.1038/mt.2015.104. Epub 2015 Jun 10.
4
CARTs for Solid Tumors: Feasible or Infeasible?嵌合抗原受体 T 细胞疗法治疗实体瘤：可行还是不可行？
Oncol Res Treat. 2017;40(9):540-546. doi: 10.1159/000477095. Epub 2017 Aug 17.
5
Engineering T cells for adoptive therapy: outsmarting the tumor.工程化 T 细胞用于过继性治疗：智胜肿瘤。
Curr Opin Immunol. 2018 Apr;51:133-139. doi: 10.1016/j.coi.2018.03.014. Epub 2018 Mar 24.
6
Programming CAR-T cells to kill cancer.CAR-T 细胞疗法：以编程方式杀死癌细胞。
Nat Biomed Eng. 2018 Jun;2(6):377-391. doi: 10.1038/s41551-018-0235-9. Epub 2018 Jun 11.
7
Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors.用于实体瘤过继性免疫治疗的基因重定向T淋巴细胞。
Curr Gene Ther. 2014 Feb;14(1):52-62. doi: 10.2174/1566523213666131223130353.
8
Adoptive T-cell therapy for cancer: The era of engineered T cells.过继性细胞疗法治疗癌症：工程化 T 细胞的时代。
Eur J Immunol. 2015 Sep;45(9):2457-69. doi: 10.1002/eji.201545552. Epub 2015 Aug 21.
9
T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.基于 T 细胞的免疫疗法：过继细胞转移和检查点抑制。
Cancer Immunol Res. 2015 Oct;3(10):1115-22. doi: 10.1158/2326-6066.CIR-15-0190.
10
Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins.通过工程化的 CD19 融合蛋白重新靶向 CD19 嵌合抗原受体 T 细胞。
Mol Pharm. 2019 Aug 5;16(8):3544-3558. doi: 10.1021/acs.molpharmaceut.9b00418. Epub 2019 Jul 15.
引用本文的文献
1
Electroporation of mRNA as a Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.将mRNA电穿孔作为一种通用技术平台，用于用抗原和功能蛋白转染多种原代细胞。
Methods Mol Biol. 2024;2786:219-235. doi: 10.1007/978-1-0716-3770-8_10.
2
T Cell Microvilli: Finger-Shaped External Structures Linked to the Fate of T Cells.T细胞微绒毛：与T细胞命运相关的指状外部结构
Immune Netw. 2023 Feb 21;23(1):e3. doi: 10.4110/in.2023.23.e3. eCollection 2023 Feb.
3
Beyond lymphopenia, unraveling radiation-induced leucocyte subpopulation kinetics and mechanisms through modeling approaches.超越淋巴细胞减少症，通过建模方法揭示辐射诱导的白细胞亚群动力学和机制。
J Exp Clin Cancer Res. 2023 Feb 22;42(1):50. doi: 10.1186/s13046-023-02621-4.
4
In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes.基于体外机器学习的 CAR T 免疫突触质量测量与患者临床结果相关。
PLoS Comput Biol. 2022 Mar 18;18(3):e1009883. doi: 10.1371/journal.pcbi.1009883. eCollection 2022 Mar.
5
Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.同基因小鼠癌症模型中CAR-T细胞疗法免疫旁观者效应的分析与增强
Mol Ther Oncolytics. 2020 Jul 15;18:360-371. doi: 10.1016/j.omto.2020.07.005. eCollection 2020 Sep 25.
6
Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy.针对头颈癌的免疫反应：生物学机制及其对治疗的影响。
Transl Oncol. 2020 Feb;13(2):262-274. doi: 10.1016/j.tranon.2019.11.008. Epub 2019 Dec 21.
7
Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.免疫突触预测嵌合抗原受体细胞的疗效。
Mol Ther. 2018 Apr 4;26(4):963-975. doi: 10.1016/j.ymthe.2018.01.020. Epub 2018 Mar 2.
8
Advancing Immune and Cell-Based Therapies Through Imaging.通过成像推进免疫和基于细胞的疗法。
Mol Imaging Biol. 2017 Jun;19(3):379-384. doi: 10.1007/s11307-017-1069-7.
9
Towards a commercial process for the manufacture of genetically modified T cells for therapy.迈向用于治疗的基因改造T细胞制造的商业化流程。
Cancer Gene Ther. 2015 Mar;22(2):72-8. doi: 10.1038/cgt.2014.78. Epub 2015 Jan 23.
10
Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.用于癌症过继性免疫治疗的嵌合抗原受体：最新研究与未来展望
Mol Cancer. 2014 Sep 21;13:219. doi: 10.1186/1476-4598-13-219.
本文引用的文献
1
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.鉴定一种源自肌联蛋白的 HLA-A1 呈递肽作为工程化 MAGE A3 定向 T 细胞的交叉反应靶标。
Sci Transl Med. 2013 Aug 7;5(197):197ra103. doi: 10.1126/scitranslmed.3006034.
2
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.在骨髓瘤和黑色素瘤中，亲和增强的 T 细胞的心血管毒性和肌联蛋白交叉反应性。
Blood. 2013 Aug 8;122(6):863-71. doi: 10.1182/blood-2013-03-490565. Epub 2013 Jun 14.
3
Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.嵌合受体修饰的人 T 细胞对肿瘤基质的抗肿瘤作用。
Mol Ther. 2013 Aug;21(8):1611-20. doi: 10.1038/mt.2013.110. Epub 2013 Jun 4.
4
Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.嵌合抗原受体包含 ICOS 信号域，介导针对表达 EGFRvIII 的胶质瘤的 T 细胞的特异性和高效抗肿瘤作用。
J Hematol Oncol. 2013 May 9;6:33. doi: 10.1186/1756-8722-6-33.
5
Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency.通过具有人 VEGFR-1 亲和力的嵌合抗原受体进行特异性重定向，赋予 T 淋巴细胞肿瘤杀伤能力和抗血管生成效力。
Gene Ther. 2013 Oct;20(10):970-8. doi: 10.1038/gt.2013.19. Epub 2013 May 2.
6
Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes.用基因修饰的 EGFR 特异性 T 淋巴细胞进行癌的细胞免疫治疗。
Neoplasia. 2013 May;15(5):544-53. doi: 10.1593/neo.13168.
7
Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.利用 T 淋巴细胞转移同时靶向肿瘤抗原和肿瘤血管，协同作用可诱导小鼠已建立的肿瘤消退。
Cancer Res. 2013 Jun 1;73(11):3371-80. doi: 10.1158/0008-5472.CAN-12-3913. Epub 2013 Apr 30.
8
NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.NKG2D CAR T 细胞疗法抑制 NKG2D 配体异质性肿瘤的生长。
Immunol Cell Biol. 2013 Jul;91(6):435-40. doi: 10.1038/icb.2013.17. Epub 2013 Apr 30.
9
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.嵌合抗原受体修饰的 T 细胞治疗急性淋巴细胞白血病。
N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25.
10
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.CD19 靶向 T 细胞可迅速诱导化疗耐药的成人急性淋巴细胞白血病患者达到分子缓解。
Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.
Zotero 插件